You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.

nivolumab

( nye-VOL-ue-mab )
Funding:
New Drug Funding Program
  • Nivolumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
  • Nivolumab - Advanced or Metastatic Non-Small Cell Lung Cancer
  • Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and No Prior mTOR Inhibitor
  • Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and Prior mTOR Inhibitor
  • Nivolumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck which is Platinum Resistant or Refractory
  • Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
  • Nivolumab - Adjuvant Treatment for Completely Resected Stage III or IV Melanoma
  • Nivolumab - Relapsed Classical Hodgkin Lymphoma (cHL) Post-Autologous Stem Cell Transplant (ASCT) or ASCT Ineligible
  • Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma
  • Nivolumab plus Ipilimumab - Advanced Malignant Pleural Mesothelioma
  • Nivolumab plus Ipilimumab - In Combination with Platinum Doublet Chemotherapy for First Line Metastatic or Recurrent Non-Small Cell Lung Cancer
Other Name(s): Opdivo®
Appearance:  solution mixed into larger bags of fluids

Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.

Patient Info Sheet

Sep 2021

What it is used for

  • For treating many types of cancers such as melanoma (skin), lung, renal cell (kidney), colorectal, liver, head and neck, Hodgkin lymphoma, mesothelioma and others
  • Nivolumab is an immunotherapy drug. For more information on immunotherapy, click here.


You might also be interested in